Neither the 10-k nor the clinicaltrials.gov websit
Post# of 145440
![Avatar](/images/ProfileImages/167738657_59587_mando klein.jpg)
Again, the 2:1 ratio has always been communicated by the company in every PR, call and interview.
And again: per protocol, patients can continue to receive any drug they received prior to randomization, as specified in the protocol, besides leronlimab or placebo.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)